Compare IDEXX Laboratories, Inc. (IDXX) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Trip.com Group Ltd — how do they compare? IDEXX Laboratories, Inc. trades at $572.98 (market cap $46.22B), while Trip.com Group Ltd trades at $45.58 (market cap $29.10B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Trip.com Group Ltd pays a 0.42% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | TCOM | |
|---|---|---|
Market Cap | $46.22B | $29.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $78.96 |
52-Week Low | $526.44 | $39.84 |
Enterprise Value | $47.12B | $21.75B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Trip.com (TCOM) trades at $47.12, up 2.12% today, with a bullish technical signal from moving averages and strong fundamentals including a P/E of 6.89 and net income margin of 48.65%. Recent Q2 2026 earnings guidance missed expectations, and the company accepted a $770 million antitrust penalty in China (Reuters, 2026-07-24), creating near-term uncertainty despite robust revenue growth trends from $20.0B in 2022 to $62.4B in 2025.
The stock offers value with low valuation multiples and high profitability, but regulatory risks and muted Q2 guidance pressure upside. Analyst consensus is bullish with a $59.29 price target (67.44% buy ratings), though institutional selling and antitrust concerns warrant caution for investors seeking exposure to China's travel recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
